Efficacy and Safety Study of JNJ-32729463 Compared With Moxifloxacin for the Treatment of Subjects Requiring Hospitalization for Community-Acquired Bacterial Pneumonia

NCT01198626 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

Enrollment

INDUSTRY

Sponsor class

Stopped Enrollment would not have been met prior to the end of the pneumonia season. Termination is based on slow enrollment and not related to safety or efficacy.

Conditions

Community-Acquired Bacterial Pneumonia (CABP)

Interventions

DRUG: JNJ-32729463
DRUG: moxifloxacin
DRUG: JNJ-32729463 (Open-Label)

Sponsor

Furiex Pharmaceuticals, Inc